Literature DB >> 19858217

A turn-like structure "KKPE" segment mediates the specific binding of viral protein A27 to heparin and heparan sulfate on cell surfaces.

Ping-Chen Shih1, Min-Shiang Yang1, Su-Ching Lin1, Yu Ho1, Jye-Chian Hsiao2, Da-Rong Wang3, Steve S-F Yu1, Wen Chang2, Der-Lii M Tzou4.   

Abstract

Vaccinia viral envelope protein A27 (110 amino acids) specifically interacts with heparin (HP) or heparan sulfate (HS) proteoglycans for cell surface attachment. To examine the binding mechanism, a truncated soluble form of A27 (sA27-aa; residues 21-84 of A27) with Cys(71) and Cys(72) mutated to Ala was used as the parent molecule. sA27-aa consists of two structurally distinct domains, a flexible Arg/Lys-rich heparin-binding site (HBS) (residues 21-32; (21)STKAAKKPEAKR(32)) and a rigid coiled-coil domain (residues 43-84), both essential for the specific binding. As shown by surface plasmon resonance (SPR), the binding affinity of sA27-aa for HP (K(A) = 1.25 x 10(8) m(-1)) was approximately 3 orders of magnitude stronger than that for nonspecific binding, such as to chondroitin sulfate (K(A) = 1.65 x 10(5) m(-1)). Using site-directed mutagenesis of HBS and solution NMR, we identified a "KKPE" segment with a turn-like conformation that mediates specific HP binding. In addition, a double mutant T22K/A25K in which the KKPE segment remained intact showed an extremely high affinity for HP (K(A) = 1.9 x 10(11) m(-1)). Importantly, T22K/A25K retained the binding specificity for HP and HS but not chondroitin sulfate, as shown by in vitro SPR and in vivo cell adhesion and competitive binding assays. Molecular modeling of the HBS was performed by dynamics simulations and provides an explanation of the specific binding mechanism in good agreement with the site-directed mutagenesis and SPR results. We conclude that a turn-like structure introduced by the KKPE segment in vaccinia viral envelope protein A27 is responsible for its specific binding to HP and to HS on cell surfaces.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858217      PMCID: PMC2794769          DOI: 10.1074/jbc.M109.037267

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Specificities of heparan sulphate proteoglycans in developmental processes.

Authors:  N Perrimon; M Bernfield
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Order out of chaos: assembly of ligand binding sites in heparan sulfate.

Authors:  Jeffrey D Esko; Scott B Selleck
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

Review 3.  Roles of heparan-sulphate glycosaminoglycans in cancer.

Authors:  Ram Sasisekharan; Zachary Shriver; Ganesh Venkataraman; Uma Narayanasami
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

4.  Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo.

Authors:  C L Lin; C S Chung; H G Heine; W Chang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Structural analysis of the extracellular domain of vaccinia virus envelope protein, A27L, by NMR and CD spectroscopy.

Authors:  Ta-Hsien Lin; Chih-Ming Chia; Jye-Chian Hsiao; Wen Chang; Chiao-Chu Ku; Shang-Cheng Hung; Der-Lii M Tzou
Journal:  J Biol Chem       Date:  2002-03-18       Impact factor: 5.157

6.  The envelope G3L protein is essential for entry of vaccinia virus into host cells.

Authors:  Ruzan A Izmailyan; Cheng-Yen Huang; Shamim Mohammad; Stuart N Isaacs; Wen Chang
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Chondroitin 4-O-sulfotransferase-1 regulates E disaccharide expression of chondroitin sulfate required for herpes simplex virus infectivity.

Authors:  Toru Uyama; Miho Ishida; Tomomi Izumikawa; Edward Trybala; Frank Tufaro; Tomas Bergström; Kazuyuki Sugahara; Hiroshi Kitagawa
Journal:  J Biol Chem       Date:  2006-10-13       Impact factor: 5.157

Review 8.  Cell surface heparan sulfate and its roles in assisting viral infections.

Authors:  Jian Liu; Suzanne C Thorp
Journal:  Med Res Rev       Date:  2002-01       Impact factor: 12.944

9.  Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization.

Authors:  Ronald I W Osmond; Warren C Kett; Spencer E Skett; Deirdre R Coombe
Journal:  Anal Biochem       Date:  2002-11-15       Impact factor: 3.365

10.  Disulfide bond formation at the C termini of vaccinia virus A26 and A27 proteins does not require viral redox enzymes and suppresses glycosaminoglycan-mediated cell fusion.

Authors:  Yao-Cheng Ching; Che-Sheng Chung; Cheng-Yen Huang; Yu Hsia; Yin-Liang Tang; Wen Chang
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

View more
  10 in total

1.  Vaccinia viral protein A27 is anchored to the viral membrane via a cooperative interaction with viral membrane protein A17.

Authors:  Da-Rong Wang; Jye-Chian Hsiao; Chien-Hsuan Wong; Guo-Chian Li; Su-Ching Lin; Steve S-F Yu; Wenlung Chen; Wen Chang; Der-Lii M Tzou
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

2.  Identification of amino acid residues important for heparan sulfate proteoglycan interaction within variable region 3 of the feline immunodeficiency virus surface glycoprotein.

Authors:  Qiong-Ying Hu; Elizabeth Fink; Meaghan Happer; John H Elder
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

3.  Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferation.

Authors:  Rochelle M Witt; Marie-Lyn Hecht; Maria F Pazyra-Murphy; Samuel M Cohen; Christian Noti; Toin H van Kuppevelt; Maria Fuller; Jennifer A Chan; John J Hopwood; Peter H Seeberger; Rosalind A Segal
Journal:  J Biol Chem       Date:  2013-07-18       Impact factor: 5.157

4.  Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination.

Authors:  A M Wolfe; K M Dunlap; A C Smith; M Y Bartee; E Bartee
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

5.  Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses.

Authors:  Imma Montanuy; Ali Alejo; Antonio Alcami
Journal:  FASEB J       Date:  2011-03-03       Impact factor: 5.191

6.  Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis.

Authors:  Pierre Lebrun; Dominique Raze; Bernd Fritzinger; Jean-Michel Wieruszeski; Franck Biet; Alexander Dose; Mathieu Carpentier; Dirk Schwarzer; Fabrice Allain; Guy Lippens; Camille Locht
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

7.  Crystal structure of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein.

Authors:  Tao-Hsin Chang; Shu-Jung Chang; Fu-Lien Hsieh; Tzu-Ping Ko; Cheng-Tse Lin; Meng-Ru Ho; Iren Wang; Shang-Te Danny Hsu; Rey-Ting Guo; Wen Chang; Andrew H J Wang
Journal:  PLoS Pathog       Date:  2013-08-22       Impact factor: 6.823

8.  Species-Specific Conservation of Linear Antigenic Sites on Vaccinia Virus A27 Protein Homologs of Orthopoxviruses.

Authors:  Henrike P Ahsendorf; Li L Gan; Kamal H Eltom; Ahmed Abd El Wahed; Sven-Kevin Hotop; Rachel L Roper; Ulrike Beutling; Mark Broenstrup; Christiane Stahl-Hennig; Ludwig E Hoelzle; Claus-Peter Czerny
Journal:  Viruses       Date:  2019-05-29       Impact factor: 5.048

9.  Development of a Genus-Specific Antigen Capture ELISA for Orthopoxviruses - Target Selection and Optimized Screening.

Authors:  Daniel Stern; Diana Pauly; Martin Zydek; Lilija Miller; Janett Piesker; Michael Laue; Fred Lisdat; Martin B Dorner; Brigitte G Dorner; Andreas Nitsche
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

Review 10.  Nanoparticle-based Cell Trackers for Biomedical Applications.

Authors:  Jen-Shyang Ni; Yaxi Li; Wentong Yue; Bin Liu; Kai Li
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.